MAPT and Alzheimer disease: This review outlines positron emission tomography (PET) biomarkers used in Alzheimer's disease (AD) research and clinical settings, targeting both specific (amyloid, tau) and non‐specific (neurodegeneration, synaptic density, neuroinflammation) processes.